These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 39001676)

  • 1. Establishment of an animal model of immune-related adverse events induced by immune checkpoint inhibitors.
    Meng Y; Lv Y; Shen M; Yu W; Liu Y; Liu T; Liu G; Ma S; Hui Z; Ren X; Liu L
    Cancer Med; 2024 Jul; 13(14):e70011. PubMed ID: 39001676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy.
    Ju M; Zhang J; Deng Z; Wei M; Ma L; Chen T; Zhao L
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39089739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Cytokine Signatures in Thyroiditis Induced by PD-1 or CTLA-4 Blockade: Insights from a New Mouse Model.
    Ippolito S; Di Dalmazi G; Pani F; Sabini E; Caturegli P
    Thyroid; 2021 Dec; 31(12):1839-1849. PubMed ID: 34598661
    [No Abstract]   [Full Text] [Related]  

  • 4. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model.
    Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S
    Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synergistic Effects of Nanoscale CaO
    Wang Y; Ju S; Zhou H; Bai Y; Zhou C; Liu J; Dong X; Zheng C
    Int J Nanomedicine; 2024; 19():137-154. PubMed ID: 38196507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Post-immunotherapy CTLA-4 Ig treatment improves antitumor efficacy.
    Mok S; Ağaç Çobanoğlu D; Liu H; Mancuso JJ; Allison JP
    Proc Natl Acad Sci U S A; 2024 Jul; 121(27):e2404661121. PubMed ID: 38923991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
    Ma P; Liu J; Qin J; Lai L; Heo GS; Luehmann H; Sultan D; Bredemeyer A; Bajapa G; Feng G; Jimenez J; He R; Parks A; Amrute J; Villanueva A; Liu Y; Lin CY; Mack M; Amancherla K; Moslehi J; Lavine KJ
    Circulation; 2024 Jan; 149(1):48-66. PubMed ID: 37746718
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors.
    Dougan M; Blidner AG; Choi J; Cooksley T; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Anderson R; Rapoport BL
    Support Care Cancer; 2020 Dec; 28(12):6129-6143. PubMed ID: 32856210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined use of microwave ablation and cell immunotherapy induces nonspecific immunity of hepatocellular carcinoma model mice.
    Duan X; Wang M; Han X; Ren J; Huang G; Ju S; Zhang Q
    Cell Cycle; 2020 Dec; 19(24):3595-3607. PubMed ID: 33283623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
    Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
    Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors.
    Yoshikawa Y; Imamura M; Yamauchi M; Hayes CN; Aikata H; Okamoto W; Miyata Y; Okada M; Hattori N; Sugiyama K; Yoshioka Y; Toratani S; Takechi M; Ichinohe T; Ueda T; Takeno S; Kobayashi T; Ohdan H; Teishima J; Hide M; Nagata Y; Kudo Y; Iida K; Chayama K
    BMC Cancer; 2022 Nov; 22(1):1232. PubMed ID: 36447159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.
    Mihic-Probst D; Reinehr M; Dettwiler S; Kolm I; Britschgi C; Kudura K; Maggio EM; Lenggenhager D; Rushing EJ
    Immunobiology; 2020 Sep; 225(5):152009. PubMed ID: 32962812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
    Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
    Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
    Kim K; Skora AD; Li Z; Liu Q; Tam AJ; Blosser RL; Diaz LA; Papadopoulos N; Kinzler KW; Vogelstein B; Zhou S
    Proc Natl Acad Sci U S A; 2014 Aug; 111(32):11774-9. PubMed ID: 25071169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.
    Olivo Pimentel V; Marcus D; van der Wiel AM; Lieuwes NG; Biemans R; Lieverse RI; Neri D; Theys J; Yaromina A; Dubois LJ; Lambin P
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33688020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model.
    Llopiz D; Ruiz M; Villanueva L; Iglesias T; Silva L; Egea J; Lasarte JJ; Pivette P; Trochon-Joseph V; Vasseur B; Dixon G; Sangro B; Sarobe P
    Cancer Immunol Immunother; 2019 Mar; 68(3):379-393. PubMed ID: 30547218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
    Allard B; Pommey S; Smyth MJ; Stagg J
    Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.